%20(1)_edited_p.png)
The Ultimate Guide to Small-Cap Screening Strategies
Updated: 4 days ago
Small-cap stocks - companies worth roughly $300M to $2B - are where the market is least efficient. Wall Street's biggest funds can't own them in size, so fewer analysts cover them and mispricings last longer. That's the opportunity. The problem is volume: thousands of names, most low-quality, and a few outright traps. Screening is how you turn that ocean into a short list worth researching.
Why screening matters more for small caps
A disciplined screen does two jobs at once: it surfaces companies hitting an inflection before the crowd notices, and it filters out the landmines - thin liquidity, weak balance sheets, dilution, and governance problems that are far more common down-cap.
The core screening filters
Start broad, then tighten. These filters do the most work:
Market cap $300M-$2B. The classic small-cap band. Below ~$300M, quality and liquidity drop fast.
Daily dollar volume > $1-3M. The most-skipped filter. If you can't get in and out without moving the price, nothing else matters.
Revenue growth. Screen for a consistent trend (e.g., >10% YoY), not a single quarter.
Profitability, or a clear path to it. Positive or improving operating margins. A swing from losses to profit is one of the strongest setups - see our breakdown of AMSC's profitability inflection.
Balance-sheet strength. Reasonable debt and enough cash runway that the company won't be forced to dilute you at the worst time.
Insider buying. Cluster buying - multiple insiders purchasing with their own money - is one of the strongest small-cap signals. We track it in our weekly insider-buying screens.
The red flags to screen out
Filtering out bad companies is as valuable as finding good ones. Disqualify or heavily discount:
Serial dilution. A share count that keeps climbing quietly transfers value away from you.
Going-concern language or a thin cash runway. If survival is in doubt, move on.
Restatements and internal-control weaknesses. You can't value numbers you can't trust - see Century Casinos' restatement and LifeMD's revenue-recognition warning.
Reverse splits to stay listed, and promotional management. Often a symptom, not a cure.
Free tools that do the job
Finviz - fast, free fundamental and technical screening.
SEC EDGAR full-text search - search every filing for insider buys, uplistings, or going-concern language.
TradingView - screening plus clean charting for liquidity and trend.
10-Qs and 10-Ks - the primary source. A screen gets you to the door; the filings tell you whether to walk in.
From screen to thesis
A screen is a starting point, never a buy signal. Once a name passes, read the last two 10-Qs and the latest 10-K and decide whether the trend is durable. The goal is a one-line thesis you can state plainly - a beat-and-raise with momentum, a margin turnaround, a catalyst the market hasn't priced. That's exactly the format of our per-ticker breakdowns, like Ironwood's beat-raise-and-review setup and Tactile Systems' therapy expansion.
Make screening a habit
The best opportunities recur: new insider clusters, OTC companies uplisting to the NYSE or Nasdaq, earnings inflections. Running the same screens on a schedule is how you catch them early - which is exactly what we publish every week in our Market Screens coverage.
Screening won't hand you the next big winner overnight. But a disciplined, repeatable process - find quality, filter out risk, confirm in the filings - is how you uncover value where others miss it.
Want the screens run for you every week? Subscribe to the newsletter and follow our Market Screens coverage.
Editor’s note (September 2026): This piece predates SCN’s current editorial standards and is retained as published. See how SCN works.
SCN editorial — independent commentary for information only, not investment advice.
